Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP294330.RAf49Mbz3gMWwR1oioU37RiuZG5LuBw9Sn5WIknAU3tpI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP294330.RAf49Mbz3gMWwR1oioU37RiuZG5LuBw9Sn5WIknAU3tpI130_assertion type Assertion NP294330.RAf49Mbz3gMWwR1oioU37RiuZG5LuBw9Sn5WIknAU3tpI130_head.
- NP294330.RAf49Mbz3gMWwR1oioU37RiuZG5LuBw9Sn5WIknAU3tpI130_assertion description "[Enrolled in the study were 203 patients with chronic active hepatitis C. They were all given: interferon alpha-2a (3 MU subcutaneously thrice a week) and ursodeoxycholic acid (10 mg/kg/day) for 9 months.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP294330.RAf49Mbz3gMWwR1oioU37RiuZG5LuBw9Sn5WIknAU3tpI130_provenance.
- NP294330.RAf49Mbz3gMWwR1oioU37RiuZG5LuBw9Sn5WIknAU3tpI130_assertion evidence source_evidence_literature NP294330.RAf49Mbz3gMWwR1oioU37RiuZG5LuBw9Sn5WIknAU3tpI130_provenance.
- NP294330.RAf49Mbz3gMWwR1oioU37RiuZG5LuBw9Sn5WIknAU3tpI130_assertion SIO_000772 10975752 NP294330.RAf49Mbz3gMWwR1oioU37RiuZG5LuBw9Sn5WIknAU3tpI130_provenance.
- NP294330.RAf49Mbz3gMWwR1oioU37RiuZG5LuBw9Sn5WIknAU3tpI130_assertion wasDerivedFrom befree-2016 NP294330.RAf49Mbz3gMWwR1oioU37RiuZG5LuBw9Sn5WIknAU3tpI130_provenance.
- NP294330.RAf49Mbz3gMWwR1oioU37RiuZG5LuBw9Sn5WIknAU3tpI130_assertion wasGeneratedBy ECO_0000203 NP294330.RAf49Mbz3gMWwR1oioU37RiuZG5LuBw9Sn5WIknAU3tpI130_provenance.